Lv11
50 积分 2023-09-04 加入
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
2小时前
已完结
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
25天前
已完结
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
25天前
已完结
The efficacy and safety profile of third-line treatment in patients with metastatic pancreatic adenocarcinoma
2个月前
已关闭
Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients
2个月前
已完结
Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma
2个月前
已完结
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
3个月前
已完结
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
3个月前
已完结
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes
3个月前
已完结
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis
3个月前
已完结
皖公网安备34019202002308
